free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

  • FDA approves first generics of Gilenya expresspharma
    December 09, 2019
    The US Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.
  • FDA approves generics of Novartis multiple sclerosis drug Gilenya pharmaceutical-technology
    December 09, 2019
    The US Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).
  • Novartis' key multiple sclerosis product Gilenya gets approval in China biospectrumasia
    July 20, 2019
    Chinese National Medical Products Administration (NMPA) approved Gilenya? for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older
  • Novartis' Gilenya staves off generic challengers?—for now?—after federal injunction fiercepharma
    June 28, 2019
    Novartis’ multiple sclerosis?med Gilenya is facing U.S. generic challengers on all sides to its blockbuster sales,?and the company hoped a court order could stave them off. The Swiss drugmaker got what it asked for—and it might just keep the med at the to
  • Novartis Announces EU Approval of Gilenya americanpharmaceuticalreview
    November 30, 2018
    Novartis announced the European Commission (EC) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years old with relapsing-remitting forms
  • Novartis' Gilenya scores paediatric EU approval for advanced relapsing-remitting MS pharmafile
    November 30, 2018
    Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS) in patients aged between 10 and 17 years old...
  • EU approves Gilenya for paediatric MS pharmatimes
    November 30, 2018
    European regulators have approved Novartis’ Gilenya for the treatment of children and adolescents from 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).
  • FDA Expands Approval of Gilenya americanpharmaceuticalreview
    May 18, 2018
    The U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service